TRPV2 and breast carcinoma: In contrast, the application of the TRPV2 agonist cannabidiol to MCF-7, SK-BR-3, and MDA-MB-231 breast cancer cells resulted in increased expression of ATG, LC3A, and LC3B, along with reduced SQSTM1, as observed in our quantitative PCR analysis (Figure S5A-C).